Screener
BioMarin Pharmaceuticals BMRN Business Segments — Total revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total revenues | $989,708 | $825,410 | $1,755,916 | $1,570,555 |
| Less: | ||||
| Cost of sales | 202,795 | 150,090 | 397,794 | 301,648 |
| R&D expenses | ||||
| Research and early pipeline | 85,069 | 95,968 | 172,360 | 186,438 |
| Later-stage clinical programs | 50,295 | 13,133 | 86,472 | 27,424 |
| Marketed products | 71,588 | 52,207 | 126,916 | 106,177 |
| SG&A expenses |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's business segments — total revenues?
- BioMarin Pharmaceuticals (BMRN) reported business segments — total revenues of $989.71M in Q2 2026.
- How has BioMarin Pharmaceuticals's business segments — total revenues changed year-over-year?
- BioMarin Pharmaceuticals's business segments — total revenues increased by 19.9% year-over-year, from $825.41M to $989.71M.
- What is the long-term trend for BioMarin Pharmaceuticals's business segments — total revenues?
- Over 3 years (2022 to 2025), BioMarin Pharmaceuticals's business segments — total revenues has grown at a 15.4% compound annual growth rate (CAGR), from $2.1B to $3.22B.
- What does business segments — total revenues mean?
- This represents the total gross revenue generated by the company's primary reportable business segment. It encompasses all sales of rare-disease therapies and associated pharmaceutical products within this specific operational unit. This figure serves as the top-line indicator of the segment's market penetration and product demand.
Ask your AI about BioMarin Pharmaceuticals's business segments — total revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude